The replacement of RESTORE project partner 3DTech with its spin-out Brinter Ltd has been officially approved by EU. 3DTech was founded in 2013 in Salo, Finland, and it specializes in industrial 3D printing and related solutions and services. Brinter was founded in 2018 as a 3DTech’s business unit. Brinter delivered its first bioprinter in 2019, and as a result of major R&D investments and advances, it spun out as a company of its own on 31.12.2020 to boost the growth and globalization of bioprinting technology.
Brinter specializes in developing 3D bioprinters, modules, and bioinks for clients in the biotech, pharmaceutical, research, and cosmetic industries. In March 2022, Brinter announced the release of its new extrusion-based Visco Bio print head in collaboration with Puredyne for its Brinter® bioprinters. The new modular print head enables nearly zero dead volume, meaning that expensive medical grade material waste is cut to a minimal level.
The head means more material diversity for dispensing, repeatability with a continuous and precise printing process and zero cross-contamination due to the use of a single cartridge per material. Due to the dispensing geometry, a constant volume per revolution is always conveyed and precisely applied, meaning almost zero dead volume can be achieved. The programmable suck-back ensures clean start and finish points.
“The release of this print head means that basic requirements towards Good Manufacturing Practices (GMP) are met, for example, due to no cross-contamination with the use of a single cartridge per material, used together with the disinfecting blue light module we published in December. Likewise, researchers, pharma industry, and universities benefit from the repeatability of printing results being increased due to continuous and precise printing processes,” says Tomi Kalpio, CEO of Brinter.
“The practical applications of the technology align with Brinter’s vision to improve our quality of life by shortening and enhancing the productivity of the scientific discovery process and bio-manufacturing. This pushes forward the ambition of printing human spare parts such as hearts and kidneys, as well as more personalized treatment through cancer research and drug testing,” he continues.
Visco Bio was launched in close collaboration with Puredyne, who provided the innovative market technology.
“Brinter is an innovative and strong partner for us, with whom we already have had a close relationship for some years. The Puredyne® print head, with its involved progressive cavity technology, enables a totally new precision in extrusion-based bioprinting. Moreover, our solution gives the operator the required process and material flexibility in the handling of low to high viscosity biomaterials,” says Felix Gruber, Business Development Manager at Puredyne.